CATX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CATX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Perspective Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $97.89 Mil.
During the past 12 months, Perspective Therapeutics's average Total Assets Growth Rate was 937.00% per year. During the past 3 years, the average Total Assets Growth Rate was 141.30% per year. During the past 5 years, the average Total Assets Growth Rate was 65.80% per year. During the past 10 years, the average Total Assets Growth Rate was 14.40% per year.
During the past 13 years, Perspective Therapeutics's highest 3-Year average Total Assets Growth Rate was 1792.40%. The lowest was -91.60%. And the median was -6.55%.
Total Assets is connected with ROA %. Perspective Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -94.72%. Total Assets is also linked to Revenue through Asset Turnover. Perspective Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was -0.05.
The historical data trend for Perspective Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Dec23 | |||||||||||
Total Assets | Get a 7-Day Free Trial | 9.42 | 8.70 | 70.42 | 64.44 | 97.89 |
Perspective Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Assets | Get a 7-Day Free Trial | 58.28 | 127.65 | 120.15 | 110.52 | 97.89 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Perspective Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 75.179 | + | 22.712 | |
= | 97.89 |
Perspective Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2023 ) | + | Total Liabilities (Q: Dec. 2023 ) |
= | 75.179 | + | 22.712 | |
= | 97.89 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (AMEX:CATX) Total Assets Explanation
Total Assets is connected with ROA %.
Perspective Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is
ROA % | = | Net Income (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | -98.7 | / | ( (110.518 | + | 97.891) | / 2 ) | |
= | -98.7 | / | 104.2045 | ||||
= | -94.72 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Perspective Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | -5.239 | / | ( (110.518 | + | 97.891) | / 2 ) |
= | -5.239 | / | 104.2045 | |||
= | -0.05 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Perspective Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Williamson Robert F Iii | director | 140 LASALLE AVENUE, PIEDMONT CA 94610 |
Markus Puhlmann | officer: Chief Medical Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Jonathan Robert Hunt | officer: Chief Financial Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Lori A Woods | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Heidi Henson | director | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
Frank Morich | director | 40 GUEST STREET, BOSTON MA 02135 |
Johan M. Spoor | director, officer: CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Mark John Austin | officer: Controller/Prin Fin&Acct Offic | 350 HILLS ST, STE 106, RICHLAND WA 99354 |
Philip J Vitale | director | 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255 |
Michael W Mccormick | director | 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260 |
William Cavanagh | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Alan Hoffmann | director | 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032 |
Michael Krachon | officer: VP of Sales & Marketing | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Krista Cline | officer: Dir. of Operations, Secretary | 350 HILLS STREET, STE 106, RICHLAND WA 99354 |
Jennifer Streeter | officer: VP of Human Resources | 350 HILLS STREET SUITE 106, RICHLAND WA 99354 |
From GuruFocus
By Marketwired Marketwired • 12-03-2018
By GuruFocus Research GuruFocus Editor • 04-12-2021
By Marketwired Marketwired • 09-10-2018
By Marketwired Marketwired • 08-13-2019
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 04-16-2019
By Marketwired Marketwired • 09-10-2019
By Marketwired Marketwired • 01-29-2019
By PRNewswire PRNewswire • 01-07-2021
By PRNewswire PRNewswire • 10-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.